EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposure

Himanshu Dhanda, Shamsuz Zaman, Bhavika Rishi, Raj Kamal, Manpreet Kaur, Nitika Anand, Baseer Noor, Pranay Tanwar, Sufian Zaheer, Prashant Prabhakar, Fouzia Siraj, Amitabh Singh und 1 weitere

Frontiers in Hematology · 21.05.2026 · 5

DOI: 10.3389/frhem.2026.1779396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Hematology, online erschienen am 21.05.2026. Verfasst von Himanshu Dhanda und 12 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy in India, with survival rates (60%–70%) significantly lower than in high-income countries (85%–90%). Asparaginase, a cornerstone of ALL therapy, has a narrow therapeutic window with substantial interpatient pharmacokinetic variability. However, therapeutic drug monitoring is rarely performed in resource-limited settings.

Methods

The prospective pilot study assessed serum asparaginase activity during induction therapy in Indian children with high-risk B-cell ALL. Of 30 enrolled patients, nine high-risk cases (aged 1–12 years) received L-asparaginase according to the modified ICiCLe protocol. Serum asparaginase activity was measured using a spectrophotometric assay at pre-dose (trough) and 24-h post-dose (peak) time points. Treatment-related toxicities were monitored using standardized criteria.

Results

Among the nine high-risk patients, five completed inductions, three died from treatment-related complications, and one was transferred. All evaluable patients ( n = 5) had subtherapeutic trough asparaginase activity (<0.5 IU/mL; target ≥0.5 IU/mL). Peak levels showed marked interpatient variability (range: 0.52–1.97 IU/mL; median: 1.15 IU/mL). Higher enzyme activity correlated with biochemical toxicities: hepatotoxicity (5/5), elevated blood urea nitrogen (4/5), hypertriglyceridemia (3/5), and subclinical pancreatitis (2/5).

Conclusion

This pilot study demonstrates consistently subtherapeutic trough asparaginase levels in a small cohort of Indian children with high-risk ALL, suggesting potential inadequate drug exposure during induction therapy. These findings highlight the potential role of therapeutic drug monitoring in optimizing dosing and minimizing toxicity in resource-limited settings. Larger, adequately powered studies are required to validate these observations and establish population-specific pharmacokinetic parameters and dosing strategies.

Zitieren

APA

Dhanda, H., Zaman, S., Rishi, B., Kamal, R., Kaur, M., Anand, N., Noor, B., Tanwar, P., Zaheer, S., Prabhakar, P., Siraj, F., Singh, A., & Misra, A. (2026). A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposure. Frontiers in Hematology, 5. https://doi.org/10.3389/frhem.2026.1779396

Vancouver

Dhanda H, Zaman S, Rishi B, Kamal R, Kaur M, Anand N, et al. A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposure. Frontiers in Hematology. 2026;5. doi:10.3389/frhem.2026.1779396

BibTeX
@article{Dhanda2026,
  author = {Dhanda, Himanshu and Zaman, Shamsuz and Rishi, Bhavika and Kamal, Raj and Kaur, Manpreet and Anand, Nitika and Noor, Baseer and Tanwar, Pranay and Zaheer, Sufian and Prabhakar, Prashant and Siraj, Fouzia and Singh, Amitabh and Misra, Aroonima},
  title = {A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposure},
  journal = {Frontiers in Hematology},
  year = {2026},
  volume = {5},
  doi = {10.3389/frhem.2026.1779396}
}
Kostenlos starten →